Trial Outcomes & Findings for The Use of Coconut Oil for the Prevention and Treatment of Diaper Dermatitis in the NICU Population (NCT NCT02614248)

NCT ID: NCT02614248

Last Updated: 2024-10-15

Results Overview

The number of days free from diaper dermatitis.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

149 participants

Primary outcome timeframe

Once, at hospital discharge, an average of 2 weeks

Results posted on

2024-10-15

Participant Flow

Participant milestones

Participant milestones
Measure
Coconut Oil
Participants in this group will receive a generous layer of organic, unrefined coconut oil applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding). Organic, Unrefined Coconut Oil
Standard of Care
Participants in this group will receive the standard of care for preventing and treating diaper dermatitis at Genesis. This includes no treatment until a diaper dermatitis appears. If diaper dermatitis appears, participants will receive a generous layer of Medline Remedy Phytoplex Z-Guard Skin Protectant applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding). Medline Remedy Phytoplex Z-Guard Skin Protectant
Overall Study
STARTED
75
74
Overall Study
COMPLETED
72
70
Overall Study
NOT COMPLETED
3
4

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Coconut Oil
n=75 Participants
Participants in this group will receive a generous layer of organic, unrefined coconut oil applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding). Organic, Unrefined Coconut Oil
Standard of Care
n=74 Participants
Participants in this group will receive the standard of care for preventing and treating diaper dermatitis at Genesis. This includes no treatment until a diaper dermatitis appears. If diaper dermatitis appears, participants will receive a generous layer of Medline Remedy Phytoplex Z-Guard Skin Protectant applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding). Medline Remedy Phytoplex Z-Guard Skin Protectant
Total
n=149 Participants
Total of all reporting groups
Age, Categorical
<=18 years
75 Participants
n=75 Participants
74 Participants
n=74 Participants
149 Participants
n=149 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=75 Participants
0 Participants
n=74 Participants
0 Participants
n=149 Participants
Age, Categorical
>=65 years
0 Participants
n=75 Participants
0 Participants
n=74 Participants
0 Participants
n=149 Participants
Age, Continuous
3.0 Days
n=75 Participants
3.0 Days
n=74 Participants
3.0 Days
n=149 Participants
Sex: Female, Male
Female
32 Participants
n=75 Participants
28 Participants
n=74 Participants
60 Participants
n=149 Participants
Sex: Female, Male
Male
43 Participants
n=75 Participants
46 Participants
n=74 Participants
89 Participants
n=149 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
United States
75 participants
n=75 Participants
74 participants
n=74 Participants
149 participants
n=149 Participants

PRIMARY outcome

Timeframe: Once, at hospital discharge, an average of 2 weeks

The number of days free from diaper dermatitis.

Outcome measures

Outcome measures
Measure
Coconut Oil
n=75 Participants
Participants in this group will receive a generous layer of organic, unrefined coconut oil applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding). Organic, Unrefined Coconut Oil
Standard of Care
n=74 Participants
Participants in this group will receive the standard of care for preventing and treating diaper dermatitis at Genesis. This includes no treatment until a diaper dermatitis appears. If diaper dermatitis appears, participants will receive a generous layer of Medline Remedy Phytoplex Z-Guard Skin Protectant applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding). Medline Remedy Phytoplex Z-Guard Skin Protectant
The Number of Days Free From Diaper Dermatitis
4.065 Days
Standard Deviation 0
4.274 Days
Standard Deviation 0

PRIMARY outcome

Timeframe: Once, at hospital discharge, an average of 2 weeks

The number of patients experiencing adverse events.

Outcome measures

Outcome measures
Measure
Coconut Oil
n=75 Participants
Participants in this group will receive a generous layer of organic, unrefined coconut oil applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding). Organic, Unrefined Coconut Oil
Standard of Care
n=74 Participants
Participants in this group will receive the standard of care for preventing and treating diaper dermatitis at Genesis. This includes no treatment until a diaper dermatitis appears. If diaper dermatitis appears, participants will receive a generous layer of Medline Remedy Phytoplex Z-Guard Skin Protectant applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding). Medline Remedy Phytoplex Z-Guard Skin Protectant
The Number of Patients Experiencing Adverse Events
29 Participants
22 Participants

SECONDARY outcome

Timeframe: Once, at study completion for hospital discharge, an average of 2 weeks

The percent of parents stating satisfaction with the diaper dermatitis treatment used Measured by a parent satisfaction survey

Outcome measures

Outcome measures
Measure
Coconut Oil
n=66 Participants
Participants in this group will receive a generous layer of organic, unrefined coconut oil applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding). Organic, Unrefined Coconut Oil
Standard of Care
n=65 Participants
Participants in this group will receive the standard of care for preventing and treating diaper dermatitis at Genesis. This includes no treatment until a diaper dermatitis appears. If diaper dermatitis appears, participants will receive a generous layer of Medline Remedy Phytoplex Z-Guard Skin Protectant applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding). Medline Remedy Phytoplex Z-Guard Skin Protectant
The Percent of Parents Stating Satisfaction With the Diaper Dermatitis Treatment Used
60 Participants
55 Participants

Adverse Events

Coconut Oil

Serious events: 0 serious events
Other events: 29 other events
Deaths: 0 deaths

Standard of Care

Serious events: 0 serious events
Other events: 23 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Coconut Oil
n=75 participants at risk
Participants in this group will receive a generous layer of organic, unrefined coconut oil applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding). Organic, Unrefined Coconut Oil
Standard of Care
n=74 participants at risk
Participants in this group will receive the standard of care for preventing and treating diaper dermatitis at Genesis. This includes no treatment until a diaper dermatitis appears. If diaper dermatitis appears, participants will receive a generous layer of Medline Remedy Phytoplex Z-Guard Skin Protectant applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding). Medline Remedy Phytoplex Z-Guard Skin Protectant
Respiratory, thoracic and mediastinal disorders
Respiratory syncitial virus infection
1.3%
1/75 • Number of events 1 • 1 month
1.4%
1/74 • Number of events 1 • 1 month
General disorders
Lingual frenum
1.3%
1/75 • Number of events 1 • 1 month
1.4%
1/74 • Number of events 1 • 1 month
Hepatobiliary disorders
Neonatal hyperbilirubinemia
8.0%
6/75 • Number of events 6 • 1 month
10.8%
8/74 • Number of events 8 • 1 month
Skin and subcutaneous tissue disorders
Localized eruption of skin
1.3%
1/75 • Number of events 1 • 1 month
0.00%
0/74 • 1 month
Skin and subcutaneous tissue disorders
Bleeding skin
26.7%
20/75 • Number of events 20 • 1 month
17.6%
13/74 • Number of events 13 • 1 month

Additional Information

Michelle Martin, RN

Genesis Medical Center

Phone: 562-421-7743

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place